medigraphic.com
ISSN 2007-8013 (Print)
Órgano oficial de la Universidad Autónoma de Sinaloa

2022, Number 1

<< Back Next >>

Rev Med UAS 2022; 12 (1)

Clinical-epidemiological characteristics of COVID-19 patients in a Family Medicine Unit in Reynosa, Tamaulipas

Martínez-Lara V, Morales-Ramírez D, Vázquez-Meza M

Language: Spanish
References: 16
Page: 12-20
PDF size: 102.62 Kb.


ABSTRACT

Objective: Identify the clinical-epidemiological characteristics of the patients who presented symptoms of COVID-19 at the UMF No 40 of the Instituto Mexicano del Seguro Social located in Reynosa, Tamaulipas. Material and methods: An observational, retrospective, cross-sectional, descriptive, retrospective study was carried out, using information collected in the format issued by the Mexican Ministry of Health in a total of 323 suspected patients. In addition, tests of association and mean difference were estimated. Results: It was found that, of the total respondents, 53.9% were diagnosed as positive by the Polymerase Chain Reaction (PCR) test. The most common comorbidity in this group was obesity (32.8%), followed by hypertension (23%) and diabetes (17.8%). The findings of the tests of association indicate that there is no relationship between having a certain comorbidity and testing positive. Meanwhile, the mean difference test indicates that the number of symptoms among positive patients tends to be greater than among negative patients. And it is confirmed that older people tend to be more likely to be infected than younger people. Conclusions: Each population responds differently to a disease; therefore, epidemiological studies help us to understand the behavior of a pathology in a specific context, which is why it is necessary to continue generating studies at the local level.


REFERENCES

  1. Villamil-Jiménez LC. Epidemias y pandemias:una realidad para el siglo XXI. Unmundo y una salud. Rev. Lasallista Investig. 2013; 10(1): 7-8.

  2. Organización Mundial de Salud. Preguntasfrecuentes sobre los nuevos coronavirus.[Internet]. [Consultado 12 agosto 2020].OMS; 2020. Disponible en:https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019/question-andanswers-hub/q-a-detail/q-a-coronaviruses

  3. World Health Organization. Tiempo que sobreviveel virus en las superficies. [Consultado26 de octubre de 2020] Disponible en elsitio web: https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019/advice-for-public/q-a-coronaviruses.

  4. Madrigal-Rojas JP, Quesada-Loría M, García-Sánchez M, Solano-Chinchilla A. SARSCoV-2, manifestaciones clínicas y consideracionesen el abordaje diagnóstico de COVID-19. Rev Méd Costa Rica. 2020; 85(629): 13-21.

  5. Villagrán-Olivas K, Torrontegui-Zazueta L,Entzana-Galindo A. Características clínicoepidemiológicasde pacientes de COVID-19en un Hospital de Sinaloa, México. Rev MedUAS. 2020;10 (2): 65-79.

  6. Guan Wj, Ni Zy, Hu Y, Liang Wh, Ou Cq, HeJx, et al. Clinical characteristics of coronavirusdisease 2019 in China. N Engl J Med.2020;58 (4):711-712.

  7. Huang C, Wang Y, Li X, Ren L, Zhao J, HuY, et al. Clinical features of patients infectedwith 2019 novel coronavirus in Wuhan,China. Lancet. 2020; 395 (10223):497-506.

  8. Cheung KS, Hung IFN, Chan PPY, Lung KC,Tso E, Liu R, et al. Gastrointestinal manifestationsof SARS-CoV-2 infection and virusload in fecal samples from the hong kong cohortand systematic review and meta-analysis.Gastroenterology. 2020; 159 (1): 81-95.

  9. Lechien JR, Chiesa-Estomba CM, De SiatiDR, Horoi M, Le Bon SD, Rodriguez A, et al.Olfactory and gustatory dysfunctions as aclinical presentation of mild-to-moderateforms of the coronavirus disease (COVID-19): a multicenter European study. Eur ArchOtorhinolaryngol. 2020;277 (8): 2251-226.

  10. Díaz-Castrillón FJ, Toro-Montoya AI. SARSCoV-2/COVID-19: The virus, the diseaseand the pandemic. Med & Lab. 2020; 24(3):183-205.

  11. Graham CW, Dela-Cruz C.S, Cao B, PasnickS, Jamil S. Novel Wuhan (2019-nCoV)coronavirus. Am J Respir Crit CareMed. 2020;201 (4): 7-8.

  12. Li Q, Guan X, Wu P, Wang X, Zhou L, TongY. Early transmission dynamics in Wuhan,China, of novel coronavirus-infected pneumonia.N Engl J Med. 2020; 382:1199–1207.

  13. Suárez V, Suarez-Quezada M, Oros-Ruiz S,Ronquillo De Jesús E. Epidemiology ofCOVID-19 in Mexico: from the 27th of Februaryto the 30th of April 2020. Epidemiologíade COVID-19 en México: del 27 de febreroal 30 de abril de 2020. Rev Clin Esp.2020;220(8):463-471.

  14. Secretaria de Salud 2021. COVID-19 México.[Consultado el día 9 de diciembre2020]. Disponible en el sitio web: https://datos.covid-19.conacyt.mx/#COMNac

  15. Ortiz-Brizuela E, Villanueva-Reza, González-Lara MF, Tamez-Torres KM, Román-Montes CM, Díaz-Mejía BA, et al. Característicasclínicas y epidemiológicas de pacientesdiagnosticados con COVID-19 en uncentro de atención terciaria de la Ciudad deMéxico: un estudio de cohorte prospectivo.Rev Invest Clin. 2020;72(3):165-77

  16. World Health Organization. Vigilancia de saludpública en relación con la COVID-19,Orientaciones provisionales del 7 de agostode 2020. [Consultado el 09 de diciembre del2020]. Disponible en el sitio web:https://apps.who.int/iris/bitstream/handle/10665/334000/WHO-2019-nCoV-Surveillance-Guidance-2020.7-spa.pdf




2020     |     www.medigraphic.com